Related Experiment Video

Updated: Jul 9, 2026

Establishing Cell Lines Overexpressing DR3 to Assess the Apoptotic Response to Anti-mitotic Therapeutics
12:28

Establishing Cell Lines Overexpressing DR3 to Assess the Apoptotic Response to Anti-mitotic Therapeutics

Published on: January 11, 2019

[Multiple medication resistance of apoptosis-resistant tumoral cells]

D Iu Blokhin, A A Sokolovskaia, N K Vlasenkova

    Vestnik Rossiiskoi Akademii Meditsinskikh Nauk
    |December 7, 2007
    PubMed

    Insights

    Jurkat T-lymphoblast cells (A4 clone) lost apoptosis due to programmed cell death breakdown. This resulted in tumor progression traits and multidrug resistance, impacting cancer chemotherapy effectiveness.

    Area of Science:

    • Cell Biology
    • Immunology
    • Cancer Research

    Context:

    • Jurkat T-lymphoblast cells are a model for human leukosis.
    • CD95-mediated selection was used to derive the A4 clone.
    • Apoptosis is a critical programmed cell death mechanism.

    Purpose:

    • To investigate the phenotypic changes in A4 clone cells.
    • To understand the consequences of apoptosis loss in cancer cells.
    • To assess the acquired resistance mechanisms in A4 cells.

    Summary:

    • A4 clone cells, derived from Jurkat T-lymphoblast cells, exhibit a loss of apoptosis following programmed cell death mechanism breakdown.
    • These cells display tumor progression characteristics, including oxidative stress resistance, immune suppression, and reduced growth factor dependency.
    • The loss of apoptosis correlates with the development of multidrug resistance to various chemotherapeutic agents and cytotoxins.

    Impact:

    • This study reveals a link between apoptosis evasion and aggressive tumor phenotypes.
    • The findings have implications for understanding cancer progression and therapeutic resistance.
    • Identifying these acquired properties is crucial for developing novel cancer treatment strategies.

    More Related Videos

    Enhancement of Apoptotic and Autophagic Induction by a Novel Synthetic C-1 Analogue of 7-deoxypancratistatin in Human Breast Adenocarcinoma and Neuroblastoma Cells with Tamoxifen19:44

    Enhancement of Apoptotic and Autophagic Induction by a Novel Synthetic C-1 Analogue of 7-deoxypancratistatin in Human Breast Adenocarcinoma and Neuroblastoma Cells with Tamoxifen

    Published on: May 30, 2012

    Related Concept Videos

    Treatment Resistant Cancers02:56

    Treatment Resistant Cancers

    Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
    Combination Therapies and Personalized Medicine02:50

    Combination Therapies and Personalized Medicine

    Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
    The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
    Targeted Cancer Therapies02:57

    Targeted Cancer Therapies

    The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
    There are several types of targeted therapies against specific...
    The Intrinsic Apoptotic Pathway01:31

    The Intrinsic Apoptotic Pathway

    Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
    Treatment Resistent Cancers02:56

    Treatment Resistent Cancers

    Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
    Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

    Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

    Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...